RxDoctor Payments Data

Carmela Sanchez, PA

Physician Assistant · Glenview, ILNPI 1386014629

Payments from drug & device makers

$2,500in general payments, 2019–2025

Across 99 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$979
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$504
  • Otsuka America Pharmaceutical, Inc.$444
  • Neurocrine Biosciences, Inc.$306
  • Takeda Pharmaceuticals U.S.A., Inc.$160
  • Acadia Pharmaceuticals Inc$77
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$2,500100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,500 in reported general payments places this provider in the 85th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$152,306
Medicare patients
361
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$56,425
VraylarCariprazine Hcl14$31,683
Sertraline Hcl960$12,334
Quetiapine Fumarate740$9,954
Divalproex Sodium ErDivalproex Sodium268$6,475
Trazodone Hcl492$4,948
Paliperidone ErPaliperidone11$4,836
Risperidone200$3,685
Mirtazapine174$3,518
Lorazepam225$3,005
Aripiprazole69$2,824
Escitalopram Oxalate283$2,708
Memantine Hcl106$2,461
Divalproex Sodium56$2,257
Bupropion XlBupropion Hcl105$1,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$77$56,42511 claims
AbbVieVraylar$979$31,68314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →